Brookdale Senior Living stock
BKDNYSEBrookdale Senior Living Inc., HealthcareISIN US1124631045
24Score 24 out of 100, Weak
Price and trend
32 / 100
Price history
−15% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 32% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 39).
The price is 47% below its 52-week high. Largest decline in 20 years: 96% (February 2007 to March 2020).
Chart figures for advanced users
- SMA 50$10.68
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$13.21
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)39
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.96
- The lowest closing price of the last twelve months.
- Resistance$16.77
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Brookdale Senior Living Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $2.14B, is number 29 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.12B (up 4.8% year on year) and a loss of $262.69M.
- MEQIRI Score 24 out of 100 (Weak): rank 713 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $3.25, with the price 184% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Above fair valuePrice 184% above the fair value of $3.25.Valuation 24
- DilutionShare count up 28% since 2020.Capital allocation 25
- Loss-makingLoss of $37.49M over the last 12 months.Fundamentals 21
The score is held back by profitability and growth.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
- high price swings
What lowers it
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $2.32 and expensive above $5.41 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 12.4%. At 13.4% the fair value would be $3.01, at 11.4% it would be $3.54.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 5.4% on the twelve months before. Up to 2020 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue shrank 2% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 21%, operating 1%, net −8%. Last 12 months: net −1%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 17 Feb 2027in 97 days
- Last reported
- 6 Nov 2026EPS reported −$0.06 (expected −$0.03)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.030.0%
- Revenue
- $2.92B−0.4%
- Earnings per share
- $0.17+1.0%
- Revenue
- $3B−0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −5.2%2026 guidance reaffirmed: RevPAR growth of 8% to 9% and adjusted EBITDA of $502 million to $516 million, occupancy of about 83% slightly below plan but offset by savings.
“We also remain on-track to deliver on our 2026 annual guidance of 8% to 9% RevPAR growth and adjusted EBITDA in the range of $502 million to $516 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Brookdale Senior Living
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 24
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Aveanna Healthcare HoldingsAVAH $2.86B63
- Ardent HealthARDT $2.56B60
- Pediatrix Medical GroupMD $2.46B70
- Addus HomeCareADUS $2.34B71
- Agilon HealthAGL $1.93B48
- EmeisEMEIS.PA $1.92B41
- AttendoATT.ST $1.87B65
- Healthcare Services GroupHCSG $1.7B70
ETFs that hold Brookdale Senior Living
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.19% | 0.40% | €807M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.10% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.22B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.19B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €944.34M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2006)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.